<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Medicine (Baltimore)</journal-id><journal-id journal-id-type="iso-abbrev">Medicine (Baltimore)</journal-id><journal-id journal-id-type="pmc-domain-id">2786</journal-id><journal-id journal-id-type="pmc-domain">medicine</journal-id><journal-id journal-id-type="publisher-id">MD</journal-id><journal-title-group><journal-title>Medicine</journal-title></journal-title-group><issn pub-type="ppub">0025-7974</issn><issn pub-type="epub">1536-5964</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12431741</article-id><article-id pub-id-type="pmcid-ver">PMC12431741.1</article-id><article-id pub-id-type="pmcaid">12431741</article-id><article-id pub-id-type="pmcaiid">12431741</article-id><article-id pub-id-type="pmid">39252324</article-id><article-id pub-id-type="doi">10.1097/MD.0000000000039034</article-id><article-id pub-id-type="publisher-id">MD-D-23-06279</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>5300</subject></subj-group><subj-group><subject>Research Article</subject><subject>Systematic Review and Meta-Analysis</subject></subj-group></article-categories><title-group><article-title>Progressive multiple sclerosis: A bibliometric analysis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0003-3889-0838</contrib-id><name name-style="western"><surname>Shawawrah</surname><given-names initials="M">Mays</given-names></name><degrees>MD</degrees><xref rid="aff1" ref-type="aff">a</xref><xref rid="c1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alryalat</surname><given-names initials="SA">Saif Aldeen</given-names></name><degrees>MD</degrees><email>Saifryalat@yahoo.com</email><xref rid="aff2" ref-type="aff">b</xref></contrib><aff id="aff1"><label>a</label>Department of Neurology, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan</aff><aff id="aff2"><label>b</label>Department of Ophthalmology, University of Jordan, Amman, Jordan.</aff></contrib-group><author-notes><corresp id="c1"><label>*</label>Correspondence: Mays Shawawrah, Department of Neurology, Faculty of Medicine, Jordan University of Science and Technology, Irbid 22110, Jordan (e-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mashawawrah@just.edu.jo">mashawawrah@just.edu.jo</email>).</corresp></author-notes><pub-date pub-type="collection"><day>06</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>06</day><month>9</month><year>2024</year></pub-date><volume>103</volume><issue>36</issue><issue-id pub-id-type="pmc-issue-id">470382</issue-id><elocation-id>e39034</elocation-id><history><date date-type="received"><day>26</day><month>7</month><year>2023</year></date><date date-type="received"><day>28</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>01</day><month>7</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>06</day><month>09</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>13</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-13 17:25:36.317"><day>13</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CCBY)</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="medi-103-e39034.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="medi-103-e39034.pdf"/><abstract><sec><title>Background:</title><p>Progressive multiple sclerosis (MS) is a chronic immune-mediated disease with a poorly understood pathophysiology. This bibliometric analysis of the literature aims to gain an overview of the current state of research on progressive MS.</p></sec><sec><title>Methods:</title><p>The Scopus database was searched using the terms &#8220;progressive&#8221; and &#8220;multiple sclerosis&#8221; in the title. The search was done till the 7th of January 2023. We analyzed annual trends, countries, institutions, authors, journals, articles, and keywords based primarily on the citation count.</p></sec><sec><title>Results:</title><p>One thousand nine hundred ninety-one studies out of 1993 search results were included. The included studies had 65,788 citations with a mean of 33 citations per study. Most studies were published between the years 2016 and 2020 (n&#8197;=&#8197;607) with a mean number of 20 citations. The United States of America had the highest number of publications (n&#8197;=&#8197;547) and citations (n&#8197;=&#8197;24,921). The top 3 authors were Thompson A.J., Miller D.H., and Filippi M., and <italic toggle="yes">Multiple Sclerosis Journal</italic> had the most publications (n&#8197;=&#8197;227) and citations (n&#8197;=&#8197;6849).</p></sec><sec><title>Conclusion:</title><p>To our knowledge, this is the first bibliometric study to address the topic of progressive MS in particular and potentially emphasize the direction of progressive MS research.</p></sec></abstract><kwd-group><kwd>bibliometric analysis</kwd><kwd>multiple sclerosis</kwd><kwd>progressive</kwd><kwd>scopus</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>SDC</meta-name><meta-value>T</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>1. Introduction</title><p>Multiple sclerosis (MS) is a chronic immune-mediated disease that causes inflammation, demyelination, and axonal loss in the central nervous system (CNS).<sup>[<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref>]</sup> The complexity of MS is influenced by a variety of environmental and genetic risk factors.<sup>[<xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref>]</sup> Progressive MS is clinically defined as the accumulation of disability independent of relapses, and it is a heterogeneous disease with 2 types, primary progressive and secondary progressive. Primary progressive MS manifests as an unremitting progression that starts at the onset of the disease, as opposed to secondary progressive MS, where the progression begins after an initial relapsing-remitting course.<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup> Furthermore, the pathologic mechanisms underlying progressive MS are complex, with multiple pathways involved.<sup>[<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref>]</sup> A study by Brown et al showed that managing the disease early using disease-modifying therapies decreases the risk of conversion to secondary progressive MS.<sup>[<xref rid="R8" ref-type="bibr">8</xref>]</sup> It is crucial to clarify the difference in terminology between disease &#8220;progression&#8221; and &#8220;worsening&#8221; in MS. Disease progression is a phase of MS characterized by an accrual of disability independent of relapses, whereas worsening describes any increase in disability, with or without relapses.<sup>[<xref rid="R5" ref-type="bibr">5</xref>]</sup></p><p>The 2017 McDonald diagnostic criteria states that primary progressive MS can be diagnosed in patients suffering from a one-year history of disability progression, determined either retrospectively or prospectively, independent of clinical relapses, in addition to 2 of the following criteria: (1) One or more T2 lesions characteristic of MS in typical brain region(s). (2) 2 or more T2 lesions in the spinal cord, and (3) the presence of cerebral spinal fluid-specific oligoclonal bands.<sup>[<xref rid="R9" ref-type="bibr">9</xref>]</sup></p><p>Patients may have a single symptom or multiple symptoms. Optic neuritis, brainstem syndromes, and spinal cord syndromes are the most frequently observed presentations, and there are fewer common presentations including cortical ones like dominant parietal lobe syndromes.<sup>[<xref rid="R3" ref-type="bibr">3</xref>]</sup> The main approach of treatment nowadays includes treating acute disease attacks, managing symptoms, and attempting to minimize biological activity through disease-modifying therapies.<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup></p><p>Bibliometrics is the statistical analysis of published data from books, journal articles, datasets, blogs, and their relevant attributes, such as abstracts, keywords, and citations, to describe or illustrate relationships among published works. It can be used to find key publications, works, and writers in a particular area of study. Additionally, it allows us to spot gaps in the literature, as well as understand the field&#8217;s aspects.<sup>[<xref rid="R11" ref-type="bibr">11</xref>]</sup> Bibliometric studies in the field of MS are scarce.<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup> This study aims to perform a bibliometric analysis of the literature on progressive multiple sclerosis to gain an overview of the current state of research on progressive MS.</p></sec><sec sec-type="methods"><title>2. Materials and methods</title><sec sec-type="methods"><title>2.1. Data collection and retrieval methods</title><p>Two authors searched the Scopus database independently (M.S. and S.A.A.) using the terms &#8220;progressive&#8221; and &#8220;multiple sclerosis&#8221; in the title only. The authors reached a mutual decision to use the following search algorithm:</p><disp-formula><mml:math id="M1" overflow="scroll"><mml:mstyle displaystyle="true"><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mstyle displaystyle="true"><mml:mi>T</mml:mi><mml:mi>I</mml:mi><mml:mi>T</mml:mi><mml:mi>L</mml:mi><mml:mi>E</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mspace width="thinmathspace"/><mml:mi>p</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mtext>&#8201;</mml:mtext></mml:mrow><mml:mi>A</mml:mi><mml:mi>N</mml:mi><mml:mi>D</mml:mi><mml:mrow><mml:mtext>&#8201;</mml:mtext></mml:mrow><mml:mi>T</mml:mi><mml:mi>I</mml:mi><mml:mi>T</mml:mi><mml:mi>L</mml:mi><mml:mi>E</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mi>u</mml:mi><mml:mi>l</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>p</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mrow><mml:mtext>&#8201;</mml:mtext></mml:mrow><mml:mi>s</mml:mi><mml:mi>c</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mstyle></mml:mtd></mml:mtr></mml:mtable></mml:mstyle></mml:math></disp-formula><p>Retracted articles and articles with missing information were excluded from the study. All document types were included: articles, reviews, conference papers, letters, notes, editorials, short surveys, book chapters, and errata. Articles written in languages other than English were also included (Fig. <xref rid="F1" ref-type="fig">1</xref>). The search query was done up to January 7th, 2023. Different names of the same journal were manually added as one. An institutional review board approval was not necessary due to the nature of this bibliometric study.</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><p>Flow chart of search results and exclusion criteria.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-103-e39034-g001.jpg"/></fig></sec><sec><title>2.2. Data analysis</title><p>All analyses were based primarily on citation count. We analyzed annual trends, countries, institutions, authors, journals, articles, and keywords. Tables and figures were used to facilitate the readability of analysis results. All tables and figures were generated using VOSViewer version 1.6.18 (Leiden University, The Netherlands) and Microsoft Excel (Microsoft, Redmond, Washington). A flow chart was used to demonstrate included and excluded studies. We limited the keyword occurrences to a minimum of 2 in the keyword analysis. We also manually removed words that implied the study design such as &#8220;clinical trial&#8221; or &#8220;retrospective study,&#8221; and &#8220;case-control&#8221; and redundant words such as &#8220;human,&#8221; &#8220;male,&#8221; &#8220;female,&#8221; &#8220;adult,&#8221; etc. Annual trends were analyzed by examining the number of publications in groups of 5 years each, and the mean (&#177;standard deviation) number of citations for all the documents in each group.</p></sec></sec><sec sec-type="results"><title>3. Results</title><sec><title>3.1. Included studies</title><p>We have included 1991 studies out of 1993 search results. One study was excluded due to missing information, and another study was excluded due to retraction. As for document type, 1526 studies were articles, 191 studies were reviews, and the rest were conference papers, editorials, errata, letters, notes, and short surveys (n&#8197;=&#8197;274) (Fig. <xref rid="F1" ref-type="fig">1</xref>). All included studies were cited a total number of 65,788 times, with a mean (standard deviation, SD) of 33.0 (77.5) citations per study.</p></sec><sec><title>3.2. Annual trends</title><p>Most studies in our analysis were published between the years 2016 and 2020 (n&#8197;=&#8197;607) with a mean (SD) number of citations of 20.0 (52.2). Up to and including the year 2000 there were 338 studies published in the field of progressive MS with a mean (SD) of 54.3 (97.8) citations. The third most published in year group was between 2021 and 2023 (n&#8197;=&#8197;330) and had a mean (SD) citation of 3.08 (6.18) (Table S1, Supplemental Digital Content, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/MD/N412" ext-link-type="uri">http://links.lww.com/MD/N412</ext-link>).</p></sec><sec><title>3.3. Countries</title><p>We have found that institutes from the United States of America (USA) had the highest number of publications and citations in this field (n&#8197;=&#8197;547 and n&#8197;=&#8197;24,921 respectively). Followed by the United Kingdom (UK), Italy, Germany, and Canada (Table <xref rid="T1" ref-type="table">1</xref>). In citation analysis, there were 8 clusters the largest of which were Germany, Netherlands, Poland, and others. The second cluster contained Canada, Belgium, and Turkey among others. The visualization of each country&#8217;s contribution and their interconnections is shown in Figure <xref rid="F2" ref-type="fig">2</xref>.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Publications and citations of the top-contributing countries.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Country</th><th align="center" rowspan="1" colspan="1">Publications</th><th align="center" rowspan="1" colspan="1">Citations</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">United States</td><td align="center" rowspan="1" colspan="1">547</td><td align="center" rowspan="1" colspan="1">24,921</td></tr><tr><td align="left" rowspan="1" colspan="1">United Kingdom</td><td align="center" rowspan="1" colspan="1">388</td><td align="center" rowspan="1" colspan="1">22,288</td></tr><tr><td align="left" rowspan="1" colspan="1">Italy</td><td align="center" rowspan="1" colspan="1">334</td><td align="center" rowspan="1" colspan="1">13,389</td></tr><tr><td align="left" rowspan="1" colspan="1">Germany</td><td align="center" rowspan="1" colspan="1">247</td><td align="center" rowspan="1" colspan="1">8863</td></tr><tr><td align="left" rowspan="1" colspan="1">Canada</td><td align="center" rowspan="1" colspan="1">149</td><td align="center" rowspan="1" colspan="1">8480</td></tr><tr><td align="left" rowspan="1" colspan="1">Netherlands</td><td align="center" rowspan="1" colspan="1">126</td><td align="center" rowspan="1" colspan="1">6647</td></tr><tr><td align="left" rowspan="1" colspan="1">Spain</td><td align="center" rowspan="1" colspan="1">138</td><td align="center" rowspan="1" colspan="1">6233</td></tr><tr><td align="left" rowspan="1" colspan="1">France</td><td align="center" rowspan="1" colspan="1">117</td><td align="center" rowspan="1" colspan="1">5859</td></tr><tr><td align="left" rowspan="1" colspan="1">Switzerland</td><td align="center" rowspan="1" colspan="1">89</td><td align="center" rowspan="1" colspan="1">4962</td></tr><tr><td align="left" rowspan="1" colspan="1">Belgium</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">2625</td></tr><tr><td align="left" rowspan="1" colspan="1">Australia</td><td align="center" rowspan="1" colspan="1">62</td><td align="center" rowspan="1" colspan="1">2431</td></tr><tr><td align="left" rowspan="1" colspan="1">Austria</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">2413</td></tr><tr><td align="left" rowspan="1" colspan="1">Denmark</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">2176</td></tr><tr><td align="left" rowspan="1" colspan="1">Poland</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">2150</td></tr><tr><td align="left" rowspan="1" colspan="1">Israel</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">2021</td></tr><tr><td align="left" rowspan="1" colspan="1">Sweden</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">1802</td></tr><tr><td align="left" rowspan="1" colspan="1">Turkey</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">1351</td></tr><tr><td align="left" rowspan="1" colspan="1">Czech Republic</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">1145</td></tr><tr><td align="left" rowspan="1" colspan="1">Hungary</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">918</td></tr><tr><td align="left" rowspan="1" colspan="1">Argentina</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">912</td></tr><tr><td align="left" rowspan="1" colspan="1">Portugal</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">822</td></tr><tr><td align="left" rowspan="1" colspan="1">Iran</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">792</td></tr><tr><td align="left" rowspan="1" colspan="1">Greece</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">784</td></tr><tr><td align="left" rowspan="1" colspan="1">Japan</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1">716</td></tr><tr><td align="left" rowspan="1" colspan="1">Ireland</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">629</td></tr><tr><td align="left" rowspan="1" colspan="1">Finland</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">613</td></tr><tr><td align="left" rowspan="1" colspan="1">Kuwait</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">602</td></tr><tr><td align="left" rowspan="1" colspan="1">China</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">466</td></tr><tr><td align="left" rowspan="1" colspan="1">Russia</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">459</td></tr><tr><td align="left" rowspan="1" colspan="1">Norway</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">453</td></tr></tbody></table></table-wrap><fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><p>Countries visualization.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-103-e39034-g002.jpg"/></fig></sec><sec><title>3.4. Institutions</title><p>Based on the number of publications, the top contributing institute was Novartis Pharma AG (n&#8197;=&#8197;15) from Switzerland, followed by the National Hospital for Neurology and Neurosurgery (n&#8197;=&#8197;11) from the UK, and Cleveland Clinic (Mellen Center for Multiple Sclerosis Treatment and Research) (n&#8197;=&#8197;11) from the USA. In terms of citation count, Barts and the London School of Medicine and Dentistry from the UK had the highest citation count (n&#8197;=&#8197;1488). Following it also from the UK, University College London (Institute of Neurology, Department of Clinical Neurology) (n&#8197;=&#8197;1276). Following them, are the University Hospital Basel (n&#8197;=&#8197;1052), and the University of California (n&#8197;=&#8197;1051) (Table <xref rid="T2" ref-type="table">2</xref>).</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Top-contributing institutions according to the number of publications, and citations.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Institutions&#8212;According to no. of publications</th><th align="center" rowspan="1" colspan="1">Country</th><th align="center" rowspan="1" colspan="1">Publications</th><th align="center" rowspan="1" colspan="1">Citations</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Novartis Pharma AG</td><td align="center" rowspan="1" colspan="1">Switzerland</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">906</td></tr><tr><td align="left" rowspan="1" colspan="1">National Hospital for Neurology and Neurosurgery</td><td align="center" rowspan="1" colspan="1">UK</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">407</td></tr><tr><td align="left" rowspan="1" colspan="1">Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">387</td></tr><tr><td align="left" rowspan="1" colspan="1">Icahn School of Medicine (Department of Neurology)</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">106</td></tr><tr><td align="left" rowspan="1" colspan="1">Biogen Inc.</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">349</td></tr><tr><td align="left" rowspan="1" colspan="1">London School of Hygiene and Tropical Medicine</td><td align="center" rowspan="1" colspan="1">UK</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">537</td></tr><tr><td align="left" rowspan="1" colspan="1">University College London (Institute of Neurology, Department of Neuroinflammation)</td><td align="center" rowspan="1" colspan="1">UK</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">708</td></tr><tr><td align="left" rowspan="1" colspan="1">University College London (Institute of Neurology, NMR Research Unit)</td><td align="center" rowspan="1" colspan="1">UK</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">761</td></tr><tr><td align="left" rowspan="1" colspan="1">Blizard Institute, Queen Mary University of London</td><td align="center" rowspan="1" colspan="1">UK</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">506</td></tr><tr><td align="left" rowspan="1" colspan="1">University Ospedale San Raffaele (Department of Neurology)</td><td align="center" rowspan="1" colspan="1">Italy</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">485</td></tr><tr><td align="left" rowspan="1" colspan="1">National Institute for Health Research, University College London Hospitals (Biomedical Research Centre)</td><td align="center" rowspan="1" colspan="1">UK</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">111</td></tr><tr><td align="left" rowspan="1" colspan="1">Schering AG</td><td align="center" rowspan="1" colspan="1">Germany</td><td align="center" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">273</td></tr><tr><td align="left" rowspan="1" colspan="1">University College London (Institute of Neurology, Department of Clinical Neurology)</td><td align="center" rowspan="1" colspan="1">UK</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1276</td></tr><tr><td align="left" rowspan="1" colspan="1">University of Cambridge (Department of Clinical Neurosciences)</td><td align="center" rowspan="1" colspan="1">UK</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">538</td></tr><tr><td align="left" rowspan="1" colspan="1">Royal Free Hospital (Department of Neurology)</td><td align="center" rowspan="1" colspan="1">UK</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">147</td></tr><tr><td align="left" rowspan="1" colspan="1">F. Hoffmann-La Roche Ltd</td><td align="center" rowspan="1" colspan="1">Switzerland</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">249</td></tr><tr><td align="left" rowspan="1" colspan="1">NeuroRx Research</td><td align="center" rowspan="1" colspan="1">Canada</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">772</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Institutions&#8212;According to no. of citations</th><th align="center" rowspan="1" colspan="1">Country</th><th align="center" rowspan="1" colspan="1">Publications</th><th align="center" rowspan="1" colspan="1">Citations</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Barts and the London School of Medicine and Dentistry</td><td align="center" rowspan="1" colspan="1">UK</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">1488</td></tr><tr><td align="left" rowspan="1" colspan="1">University College London (Institute of Neurology, Department of Clinical Neurology)</td><td align="center" rowspan="1" colspan="1">UK</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1276</td></tr><tr><td align="left" rowspan="1" colspan="1">University Hospital Basel</td><td align="center" rowspan="1" colspan="1">Switzerland</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">1052</td></tr><tr><td align="left" rowspan="1" colspan="1">University of California</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">1051</td></tr><tr><td align="left" rowspan="1" colspan="1">McGill University</td><td align="center" rowspan="1" colspan="1">Canada</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">1017</td></tr><tr><td align="left" rowspan="1" colspan="1">Istituto Superiore Di Sanit&#224; (Department of Cell Biology and Neuroscience)</td><td align="center" rowspan="1" colspan="1">Italy</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">983</td></tr><tr><td align="left" rowspan="1" colspan="1">Genentech Inc.</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">970</td></tr><tr><td align="left" rowspan="1" colspan="1">Istituto Superiore Di Sanit&#224; (Department of Cell Biology and Neuroscience)</td><td align="center" rowspan="1" colspan="1">Italy</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">967</td></tr><tr><td align="left" rowspan="1" colspan="1">Imperial College London (Department of Cellular and Molecular Neuroscience)</td><td align="center" rowspan="1" colspan="1">UK</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">967</td></tr><tr><td align="left" rowspan="1" colspan="1">Denver Veterans Affairs Medical Center</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">962</td></tr><tr><td align="left" rowspan="1" colspan="1">University of Colorado (Department of Immunology)</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">962</td></tr><tr><td align="left" rowspan="1" colspan="1">University of Colorado (Department of Medicine)</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">962</td></tr><tr><td align="left" rowspan="1" colspan="1">University of Colorado (Department of Microbiology)</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">962</td></tr><tr><td align="left" rowspan="1" colspan="1">University of Colorado (Department of Neurology)</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">962</td></tr><tr><td align="left" rowspan="1" colspan="1">University of Colorado (Department of Neurosurgery)</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">962</td></tr><tr><td align="left" rowspan="1" colspan="1">University of Colorado (Department of Pathology)</td><td align="center" rowspan="1" colspan="1">US</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">962</td></tr><tr><td align="left" rowspan="1" colspan="1">University Hospital Basel (Department of Neurology)</td><td align="center" rowspan="1" colspan="1">Switzerland</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">960</td></tr><tr><td align="left" rowspan="1" colspan="1">University Vita-Salute San Raffaele</td><td align="center" rowspan="1" colspan="1">Italy</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">959</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>UK <bold>=</bold> United Kingdom, US <bold>=</bold> United States</p></fn></table-wrap-foot></table-wrap></sec><sec><title>3.5. Authors</title><p>A total of 8140 authors were included in our analysis, of which 3902 had at least 25 citations. One hundred fourteen authors authored at least 10 documents, and 407 were authors on at least 5 documents about progressive multiple sclerosis. Table <xref rid="T3" ref-type="table">3</xref> shows the top 15 most cited authors. The top 3 authors were Thompson A.J., Miller D.H., and Filippi M. who have got over 19,876 citations in their multiple sclerosis publications. A cluster map of some of the most collaborative authors is shown in Figure <xref rid="F3" ref-type="fig">3</xref>. A more thorough list of top-cited authors is summarized in Table S2, Supplemental Digital Content, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://links.lww.com/MD/N412" ext-link-type="uri">http://links.lww.com/MD/N412</ext-link>.</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>Top 15 most cited authors.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Author</th><th align="center" rowspan="1" colspan="1">Documents</th><th align="center" rowspan="1" colspan="1">Citations</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Thompson A.J.</td><td align="center" rowspan="1" colspan="1">86</td><td align="center" rowspan="1" colspan="1">8473</td></tr><tr><td align="left" rowspan="1" colspan="1">Miller D.H.</td><td align="center" rowspan="1" colspan="1">73</td><td align="center" rowspan="1" colspan="1">7187</td></tr><tr><td align="left" rowspan="1" colspan="1">Filippi M.</td><td align="center" rowspan="1" colspan="1">62</td><td align="center" rowspan="1" colspan="1">4216</td></tr><tr><td align="left" rowspan="1" colspan="1">Comi G.</td><td align="center" rowspan="1" colspan="1">67</td><td align="center" rowspan="1" colspan="1">4178</td></tr><tr><td align="left" rowspan="1" colspan="1">Montalban X.</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">4005</td></tr><tr><td align="left" rowspan="1" colspan="1">Kappos L.</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">3868</td></tr><tr><td align="left" rowspan="1" colspan="1">Polman C.H.</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">3440</td></tr><tr><td align="left" rowspan="1" colspan="1">Giovannoni G.</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">2688</td></tr><tr><td align="left" rowspan="1" colspan="1">Weiner H.L.</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">2616</td></tr><tr><td align="left" rowspan="1" colspan="1">Hartung H.-P.</td><td align="center" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">2512</td></tr><tr><td align="left" rowspan="1" colspan="1">Nicholas R.</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">2452</td></tr><tr><td align="left" rowspan="1" colspan="1">Freedman M.S.</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">2369</td></tr><tr><td align="left" rowspan="1" colspan="1">Magliozzi R.</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">2306</td></tr><tr><td align="left" rowspan="1" colspan="1">McDonald W.I.</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">2297</td></tr><tr><td align="left" rowspan="1" colspan="1">Hauser S.L.</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">2271</td></tr></tbody></table></table-wrap><fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><p>Visualization of the most cited authors.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-103-e39034-g003.jpg"/></fig></sec><sec><title>3.6. Journals</title><p><italic toggle="yes">Multiple Sclerosis Journal</italic> had the most publications (n&#8197;=&#8197;227), <italic toggle="yes">Multiple Sclerosis and Related Disorders</italic> (n&#8197;=&#8197;86). By citation number, Multiple Sclerosis Journal was the most cited journal (6849), followed by <italic toggle="yes">Brain</italic> (n&#8197;=&#8197;6644), and <italic toggle="yes">Annals of Neurology</italic> (n&#8197;=&#8197;4570) as demonstrated in Table <xref rid="T4" ref-type="table">4</xref>. The top-cited journals and their interconnections between clusters are shown in Figure <xref rid="F4" ref-type="fig">4</xref>.</p><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4</label><caption><p>Number of publications and citations for the most cited journals.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Journal&#8212;Publication count sorted</th><th align="center" rowspan="1" colspan="1">Publications</th><th align="center" rowspan="1" colspan="1">Citations</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Multiple Sclerosis Journal</td><td align="center" rowspan="1" colspan="1">227</td><td align="center" rowspan="1" colspan="1">6849</td></tr><tr><td align="left" rowspan="1" colspan="1">Multiple Sclerosis and Related Disorders</td><td align="center" rowspan="1" colspan="1">86</td><td align="center" rowspan="1" colspan="1">760</td></tr><tr><td align="left" rowspan="1" colspan="1">Neurology</td><td align="center" rowspan="1" colspan="1">69</td><td align="center" rowspan="1" colspan="1">2735</td></tr><tr><td align="left" rowspan="1" colspan="1">Journal of Neurology</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">2038</td></tr><tr><td align="left" rowspan="1" colspan="1">Journal of Neuroimmunology</td><td align="center" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">1681</td></tr><tr><td align="left" rowspan="1" colspan="1">Annals of Neurology</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">4570</td></tr><tr><td align="left" rowspan="1" colspan="1">European Journal of Neurology</td><td align="center" rowspan="1" colspan="1">46</td><td align="center" rowspan="1" colspan="1">615</td></tr><tr><td align="left" rowspan="1" colspan="1">Brain</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">6644</td></tr><tr><td align="left" rowspan="1" colspan="1">Journal of Neurology Neurosurgery and Psychiatry</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">2200</td></tr><tr><td align="left" rowspan="1" colspan="1">Journal of the Neurological Sciences</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">1545</td></tr><tr><td align="left" rowspan="1" colspan="1">PLOS One</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">1455</td></tr><tr><td align="left" rowspan="1" colspan="1">Archives of Neurology</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">1900</td></tr><tr><td align="left" rowspan="1" colspan="1">Lancet Neurology</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">3609</td></tr><tr><td align="left" rowspan="1" colspan="1">Neurological Sciences</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">188</td></tr><tr><td align="left" rowspan="1" colspan="1">Acta Neurologica Scandinavica</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">476</td></tr></tbody></table><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Journal&#8212;Citation sorted</th><th align="center" rowspan="1" colspan="1">Publications</th><th align="center" rowspan="1" colspan="1">Citations</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Multiple Sclerosis Journal</td><td align="center" rowspan="1" colspan="1">227</td><td align="center" rowspan="1" colspan="1">6849</td></tr><tr><td align="left" rowspan="1" colspan="1">Brain</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1">6644</td></tr><tr><td align="left" rowspan="1" colspan="1">Annals of Neurology</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">4570</td></tr><tr><td align="left" rowspan="1" colspan="1">Lancet</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">3878</td></tr><tr><td align="left" rowspan="1" colspan="1">Lancet Neurology</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">3609</td></tr><tr><td align="left" rowspan="1" colspan="1">New England Journal of Medicine</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">3259</td></tr><tr><td align="left" rowspan="1" colspan="1">Neurology</td><td align="center" rowspan="1" colspan="1">69</td><td align="center" rowspan="1" colspan="1">2735</td></tr><tr><td align="left" rowspan="1" colspan="1">Journal of Neurology Neurosurgery and Psychiatry</td><td align="center" rowspan="1" colspan="1">43</td><td align="center" rowspan="1" colspan="1">2200</td></tr><tr><td align="left" rowspan="1" colspan="1">Journal of Neurology</td><td align="center" rowspan="1" colspan="1">63</td><td align="center" rowspan="1" colspan="1">2038</td></tr><tr><td align="left" rowspan="1" colspan="1">Archives of Neurology</td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">1900</td></tr><tr><td align="left" rowspan="1" colspan="1">Journal of Neuroimmunology</td><td align="center" rowspan="1" colspan="1">59</td><td align="center" rowspan="1" colspan="1">1681</td></tr><tr><td align="left" rowspan="1" colspan="1">Journal of The Neurological Sciences</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">1545</td></tr><tr><td align="left" rowspan="1" colspan="1">PLOS One</td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">1455</td></tr><tr><td align="left" rowspan="1" colspan="1">Brain Pathology</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">989</td></tr></tbody></table></table-wrap><fig position="float" id="F4" orientation="portrait"><label>Figure 4.</label><caption><p>Visualization of the most cited journals.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-103-e39034-g004.jpg"/></fig></sec><sec><title>3.7. Top-cited articles</title><p>Table <xref rid="T5" ref-type="table">5</xref> lists the top 10 most cited articles in the field of progressive multiple sclerosis. &#8220;Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology&#8221; by Magliozzi R. et al published in <italic toggle="yes">Brain</italic> had the most citations (n&#8197;=&#8197;967). Followed by a consensus article about multiple sclerosis treatment published in the <italic toggle="yes">New England Journal of Medicine</italic> by Kleinschmidt-DeMasters B.K. et al (n&#8197;=&#8197;962).</p><table-wrap position="float" id="T5" orientation="portrait"><label>Table 5</label><caption><p>Top 10 most cited articles.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Authors</th><th align="center" rowspan="1" colspan="1">Year</th><th align="center" rowspan="1" colspan="1">Title</th><th align="center" rowspan="1" colspan="1">Source title</th><th align="center" rowspan="1" colspan="1">Cited by</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Magliozzi R.<sup>[<xref rid="R13" ref-type="bibr">13</xref>]</sup></td><td align="center" rowspan="1" colspan="1">2007</td><td align="center" rowspan="1" colspan="1">Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology</td><td align="center" rowspan="1" colspan="1">Brain</td><td align="center" rowspan="1" colspan="1">967</td></tr><tr><td align="left" rowspan="1" colspan="1">Kleinschmidt-DeMasters B.K.<sup>[<xref rid="R14" ref-type="bibr">14</xref>]</sup></td><td align="center" rowspan="1" colspan="1">2005</td><td align="center" rowspan="1" colspan="1">Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis</td><td align="center" rowspan="1" colspan="1">New England Journal of Medicine</td><td align="center" rowspan="1" colspan="1">962</td></tr><tr><td align="left" rowspan="1" colspan="1">Kappos L.<sup>[<xref rid="R15" ref-type="bibr">15</xref>]</sup></td><td align="center" rowspan="1" colspan="1">1998</td><td align="center" rowspan="1" colspan="1">Placebo-controlled multicenter randomized trial of interferon &#946;-1b in treatment of secondary progressive multiple sclerosis</td><td align="center" rowspan="1" colspan="1">Lancet</td><td align="center" rowspan="1" colspan="1">960</td></tr><tr><td align="left" rowspan="1" colspan="1">Montalban X.<sup>[<xref rid="R16" ref-type="bibr">16</xref>]</sup></td><td align="center" rowspan="1" colspan="1">2017</td><td align="center" rowspan="1" colspan="1">Ocrelizumab versus placebo in primary progressive multiple sclerosis</td><td align="center" rowspan="1" colspan="1">New England Journal of Medicine</td><td align="center" rowspan="1" colspan="1">949</td></tr><tr><td align="left" rowspan="1" colspan="1">Serafini B.<sup>[<xref rid="R17" ref-type="bibr">17</xref>]</sup></td><td align="center" rowspan="1" colspan="1">2004</td><td align="center" rowspan="1" colspan="1">Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis</td><td align="center" rowspan="1" colspan="1">Brain Pathology</td><td align="center" rowspan="1" colspan="1">886</td></tr><tr><td align="left" rowspan="1" colspan="1">Hartung H.-P.<sup>[<xref rid="R18" ref-type="bibr">18</xref>]</sup></td><td align="center" rowspan="1" colspan="1">2002</td><td align="center" rowspan="1" colspan="1">Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomized, multicentre trial</td><td align="center" rowspan="1" colspan="1">Lancet</td><td align="center" rowspan="1" colspan="1">814</td></tr><tr><td align="left" rowspan="1" colspan="1">Hauser S.L.<sup>[<xref rid="R19" ref-type="bibr">19</xref>]</sup></td><td align="center" rowspan="1" colspan="1">1983</td><td align="center" rowspan="1" colspan="1">Intensive Immunosuppression in Progressive Multiple Sclerosis: A Randomized, Three-Arm Study of High-Dose Intravenous Cyclophosphamide, Plasma Exchange, and ACTH</td><td align="center" rowspan="1" colspan="1">New England Journal of Medicine</td><td align="center" rowspan="1" colspan="1">750</td></tr><tr><td align="left" rowspan="1" colspan="1">Mahad D.H.<sup>[<xref rid="R20" ref-type="bibr">20</xref>]</sup></td><td align="center" rowspan="1" colspan="1">2015</td><td align="center" rowspan="1" colspan="1">Pathological mechanisms in progressive multiple sclerosis</td><td align="center" rowspan="1" colspan="1">The Lancet Neurology</td><td align="center" rowspan="1" colspan="1">702</td></tr><tr><td align="left" rowspan="1" colspan="1">Hawker K.<sup>[<xref rid="R21" ref-type="bibr">21</xref>]</sup></td><td align="center" rowspan="1" colspan="1">2009</td><td align="center" rowspan="1" colspan="1">Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial</td><td align="center" rowspan="1" colspan="1">Annals of Neurology</td><td align="center" rowspan="1" colspan="1">658</td></tr><tr><td align="left" rowspan="1" colspan="1">Lassmann H.<sup>[<xref rid="R7" ref-type="bibr">7</xref>]</sup></td><td align="center" rowspan="1" colspan="1">2012</td><td align="center" rowspan="1" colspan="1">Progressive multiple sclerosis: Pathology and pathogenesis</td><td align="center" rowspan="1" colspan="1">Nature Reviews Neurology</td><td align="center" rowspan="1" colspan="1">632</td></tr></tbody></table></table-wrap></sec><sec><title>3.8. Keywords</title><p>The top 20 most occurring keywords in the field of progressive multiple sclerosis are shown in Table <xref rid="T6" ref-type="table">6</xref>. Four keywords have occurred more than 100 times, including &#8220;Multiple sclerosis,&#8221; &#8220;Primary progressive multiple sclerosis,&#8221; &#8220;Progressive multiple sclerosis,&#8221; and &#8220;Secondary progressive multiple sclerosis.&#8221; Others include &#8220;Magnetic resonance imaging,&#8221; &#8220;MRI,&#8221; &#8220;Disability,&#8221; &#8220;Neurodegeneration,&#8221; &#8220;Natalizumab,&#8221; &#8220;Biomarkers,&#8221; &#8220;Inflammation,&#8221; &#8220;Cytokines,&#8221; and &#8220;Quality of life.&#8221; The most occurring keywords as a cluster visualization are shown in Figure <xref rid="F5" ref-type="fig">5</xref>.</p><table-wrap position="float" id="T6" orientation="portrait"><label>Table 6</label><caption><p>Top 20 most occurring keywords.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">ID</th><th align="center" rowspan="1" colspan="1">Keywords</th><th align="center" rowspan="1" colspan="1">Occurrences</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">Multiple sclerosis</td><td align="center" rowspan="1" colspan="1">798</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="center" rowspan="1" colspan="1">Primary progressive multiple sclerosis</td><td align="center" rowspan="1" colspan="1">126</td></tr><tr><td align="left" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">Progressive multiple sclerosis</td><td align="center" rowspan="1" colspan="1">124</td></tr><tr><td align="left" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">Secondary progressive multiple sclerosis</td><td align="center" rowspan="1" colspan="1">116</td></tr><tr><td align="left" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">MRI</td><td align="center" rowspan="1" colspan="1">80</td></tr><tr><td align="left" rowspan="1" colspan="1">6</td><td align="center" rowspan="1" colspan="1">Magnetic resonance imaging</td><td align="center" rowspan="1" colspan="1">64</td></tr><tr><td align="left" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">Disability</td><td align="center" rowspan="1" colspan="1">55</td></tr><tr><td align="left" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">Neurodegeneration</td><td align="center" rowspan="1" colspan="1">45</td></tr><tr><td align="left" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">Natalizumab</td><td align="center" rowspan="1" colspan="1">44</td></tr><tr><td align="left" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">Primary progressive</td><td align="center" rowspan="1" colspan="1">41</td></tr><tr><td align="left" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">Secondary progressive</td><td align="center" rowspan="1" colspan="1">41</td></tr><tr><td align="left" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">Progressive</td><td align="center" rowspan="1" colspan="1">34</td></tr><tr><td align="left" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">Progressive multifocal leukoencephalopathy</td><td align="center" rowspan="1" colspan="1">34</td></tr><tr><td align="left" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">Treatment</td><td align="center" rowspan="1" colspan="1">31</td></tr><tr><td align="left" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">Cerebrospinal fluid</td><td align="center" rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">Cognition</td><td align="center" rowspan="1" colspan="1">29</td></tr><tr><td align="left" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">Biomarkers</td><td align="center" rowspan="1" colspan="1">28</td></tr><tr><td align="left" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">Progression</td><td align="center" rowspan="1" colspan="1">27</td></tr><tr><td align="left" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">Rehabilitation</td><td align="center" rowspan="1" colspan="1">27</td></tr><tr><td align="left" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">Inflammation</td><td align="center" rowspan="1" colspan="1">26</td></tr><tr><td align="left" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">Mitoxantrone</td><td align="center" rowspan="1" colspan="1">26</td></tr><tr><td align="left" rowspan="1" colspan="1">22</td><td align="center" rowspan="1" colspan="1">Biomarker</td><td align="center" rowspan="1" colspan="1">25</td></tr><tr><td align="left" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">Cytokines</td><td align="center" rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">Disease progression</td><td align="center" rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">Neuroprotection</td><td align="center" rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">Siponimod</td><td align="center" rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">Demyelination</td><td align="center" rowspan="1" colspan="1">23</td></tr><tr><td align="left" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1">Fatigue</td><td align="center" rowspan="1" colspan="1">23</td></tr><tr><td align="left" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1">Ocrelizumab</td><td align="center" rowspan="1" colspan="1">23</td></tr><tr><td align="left" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1">Quality of Life</td><td align="center" rowspan="1" colspan="1">23</td></tr><tr><td align="left" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">Atrophy</td><td align="center" rowspan="1" colspan="1">21</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>MRI = magnetic resonance imaging.</p></fn></table-wrap-foot></table-wrap><fig position="float" id="F5" orientation="portrait"><label>Figure 5.</label><caption><p>Visualization of the most occurring keywords and their interconnection across the years.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="medi-103-e39034-g005.jpg"/></fig></sec></sec><sec sec-type="discussion"><title>4. Discussion</title><p>In 2020, 2.8 million people were predicted to have MS globally, with females being more likely to develop the disease than males.<sup>[<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref>]</sup> The primary progressive type of MS disease affects fewer than 10% of MS patients.<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup> The burden of MS is affected by age and coexisting morbidities.<sup>[<xref rid="R24" ref-type="bibr">24</xref>&#8211;<xref rid="R26" ref-type="bibr">26</xref>]</sup> Our bibliometric study on progressive MS research covered up to January 7th, 2023 and included 1991 articles. According to a bibliometric study on progressive MS, more articles have been published about the disease over the past 20 years. This significant growth may be attributable to rising public awareness of the burden of progressive MS, significant technological advancements in diagnostic techniques, and a notable rise in the number of clinical trials that have been registered recently.<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup></p><p>A thorough understanding of the biological mechanism of progression is essential to develop treatments for progressive MS.<sup>[<xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R27" ref-type="bibr">27</xref>]</sup> The inflammation linked with progression is characterized by inflammatory processes within the parenchyma behind a closed or repaired blood-brain barrier, in addition to the presence of chronic active and/or slowly expanding lesions and microglia at the edges.<sup>[<xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref>]</sup> Recent trials have led to the approval of Ocrelizumab in primary progressive MS and Siponimod in secondary progressive MS.<sup>[<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R29" ref-type="bibr">29</xref>]</sup> Also, the Food Drug Administration has approved that all effective agents for relapsing MS can also be used in the treatment of secondary MS with evidence of activity manifested as clinical relapses, however, not for new lesions on magnetic resonance imaging.<sup>[<xref rid="R27" ref-type="bibr">27</xref>]</sup></p><p>The USA, the UK, Italy, Germany, and Canada are the top 5 countries in our analysis based on the number of publications. which is consistent with Aleixandre-Benavent et al findings and those of Ismail et al&#8217;s in their bibliometric analysis of MS in general, but in contrast to our stranding, they showed that Italy had more publications than the UK.<sup>[<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R30" ref-type="bibr">30</xref>]</sup> This could be a result of the vast difference in the number of articles included and the inclusion standards used in each study. According to a study by Aleixandre-Benavent and his colleagues, there is a slight difference between Denmark and Turkey regarding the total number of publications, but we discovered that Denmark has roughly twice as many citations as Turkey.<sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup> In line with Aleixandre-Benavent et al&#8217;s findings, the USA received the most citations, followed by the UK.<sup>[<xref rid="R30" ref-type="bibr">30</xref>]</sup></p><p>The most frequently cited journals identified in this study were slightly different from those noted in the bibliometric study conducted between 1945 and 2021.<sup>[<xref rid="R12" ref-type="bibr">12</xref>]</sup> The <italic toggle="yes">Multiple Sclerosis Journal</italic> had the most publications, but the <italic toggle="yes">Brain</italic> Journal had the most citations. The article &#8220;Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology,&#8221; which was published in <italic toggle="yes">Brain</italic>, received the most citations. It was the first research to demonstrate a relationship between the development of ectopic lymphoid tissue, clinical course, and the degree of tissue destruction in the target organ during a chronic inflammatory CNS disease. They recommended that removing lymphoid microenvironments within the CNS could be beneficial in the treatment of MS patients.<sup>[<xref rid="R13" ref-type="bibr">13</xref>]</sup> In a review of MS therapeutic approaches, it was noted that more research is needed to determine effective agents for the early management of the disease and to identify the ideal patient candidates. This is because effective treatment of the progression is still lacking, as current treatments only offer limited protection from the neurodegenerative component of MS.<sup>[<xref rid="R10" ref-type="bibr">10</xref>]</sup> Another bibliometric study looked at the biomedical research literature pertaining to advanced treatments for MS.<sup>[<xref rid="R31" ref-type="bibr">31</xref>]</sup></p><p>The disease&#8217;s gradual onset of symptoms often results in a delayed diagnosis that could make it worse. The prognosis of primary progressive MS is poor, with faster disability accumulation and an earlier time when ambulatory assistance is needed. Progressive forms of MS are more frequently associated with a motor presentation.<sup>[<xref rid="R6" ref-type="bibr">6</xref>]</sup> Thus, future studies should focus on addressing the pathophysiology and treatment of progressive MS in specific.</p><p>The current study has some drawbacks, including a possible length time-effect bias that could have affected the results. This bias occurs since older articles tend to receive more citations and the authors have a longer track record because they are more likely to have published more. It is important to consider that the quality of the bibliometric analysis is influenced by the quality level of the studies it included, for example, the abstracts are known to have documented preliminary results and low levels of accuracy. Other limitations include having generalized search criteria and not searching the Web of Science core collection or Google Scholar.</p><p>This bibliometric analysis proposes suggestions to identify areas that need additional research for future researchers and in establishing research and publication methodologies in investigations of progressive MS.</p></sec><sec><title>5. Conclusion</title><p>In conclusion, the most publications and citations on this subject, the USA was a leader in the field. Papers have been published in numerous journals, most remarkably <italic toggle="yes">Multiple Sclerosis Journal</italic>. The rise in the number of articles on this subject over the past 20 years might signify the importance of investigating progressive multiple sclerosis.</p></sec><sec><title>Author contributions</title><p><bold>Conceptualization:</bold> Mays Shawawrah, Saif Aldeen Alryalat.</p><p><bold>Data curation:</bold> Mays Shawawrah, Saif Aldeen Alryalat.</p><p><bold>Formal analysis:</bold> Mays Shawawrah.</p><p><bold>Investigation:</bold> Mays Shawawrah, Saif Aldeen Alryalat.</p><p><bold>Methodology:</bold> Mays Shawawrah, Saif Aldeen Alryalat.</p><p><bold>Project administration:</bold> Mays Shawawrah.</p><p><bold>Writing &#8211; original draft:</bold> Mays Shawawrah, Saif Aldeen Alryalat.</p><p><bold>Writing &#8211; review &amp; editing:</bold> Mays Shawawrah, Saif Aldeen Alryalat.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" id="s1" content-type="document" xlink:href="medi-103-e39034-s001.docx" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><fn-group><fn fn-type="abbr"><p>
<def-list><title>Abbreviations:</title><def-item><term>CNS</term><def><p>central nervous system</p></def></def-item><def-item><term>MS</term><def><p>multiple sclerosis</p></def></def-item><def-item><term>SD</term><def><p>standard deviation</p></def></def-item><def-item><term>UK</term><def><p>United Kingdom</p></def></def-item><def-item><term>USA</term><def><p>United States of America</p></def></def-item></def-list>
</p></fn></fn-group><fn-group><fn fn-type="COI-statement"><p>The authors have no funding and conflicts of interest to disclose.</p></fn><fn fn-type="other"><p>The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></fn><fn fn-type="supplementary-material"><p>Supplemental Digital Content is available for this article.</p></fn><fn fn-type="other"><p>How to cite this article: Shawawrah M, Alryalat SA. Progressive multiple sclerosis: A bibliometric analysis. Medicine 2024;103:36(e39034).</p></fn></fn-group><ref-list id="r2"><title>References</title><ref id="R1"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>J</given-names></name><name name-style="western"><surname>Vidal-Jordana</surname><given-names>A</given-names></name><name name-style="western"><surname>Montalban</surname><given-names>X</given-names></name></person-group>. <article-title>Multiple sclerosis: clinical aspects.</article-title><source>Curr Opin Neurol</source>. <year>2018</year>;<volume>31</volume>:<fpage>752</fpage>&#8211;<lpage>9</lpage>.<pub-id pub-id-type="pmid">30300239</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WCO.0000000000000622</pub-id></mixed-citation></ref><ref id="R2"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lassmann</surname><given-names>H</given-names></name></person-group>. <article-title>Pathogenic mechanisms associated with different clinical courses of multiple sclerosis.</article-title><source>Front Immunol</source>. <year>2019</year>;<volume>9</volume>:<fpage>3116</fpage>.<pub-id pub-id-type="pmid">30687321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.03116</pub-id><pub-id pub-id-type="pmcid">PMC6335289</pub-id></mixed-citation></ref><ref id="R3"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dobson</surname><given-names>R</given-names></name><name name-style="western"><surname>Giovannoni</surname><given-names>G</given-names></name></person-group>. <article-title>Multiple sclerosis &#8211; a review.</article-title><source>Eur J Neurol</source>. <year>2019</year>;<volume>26</volume>:<fpage>27</fpage>&#8211;<lpage>40</lpage>.<pub-id pub-id-type="pmid">30300457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ene.13819</pub-id></mixed-citation></ref><ref id="R4"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alfredsson</surname><given-names>L</given-names></name><name name-style="western"><surname>Olsson</surname><given-names>T</given-names></name></person-group>. <article-title>Lifestyle and environmental factors in multiple sclerosis.</article-title><source>Cold Spring Harb Perspect Med</source>. <year>2019</year>;<volume>9</volume>:<fpage>a028944</fpage>.<pub-id pub-id-type="pmid">29735578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/cshperspect.a028944</pub-id><pub-id pub-id-type="pmcid">PMC6444694</pub-id></mixed-citation></ref><ref id="R5"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cree</surname><given-names>BAC</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>DL</given-names></name><name name-style="western"><surname>Chataway</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Secondary progressive multiple sclerosis.</article-title><source>Neurology</source>. <year>2021</year>;<volume>97</volume>:<fpage>378</fpage>&#8211;<lpage>88</lpage>.<pub-id pub-id-type="pmid">34088878</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/WNL.0000000000012323</pub-id><pub-id pub-id-type="pmcid">PMC8397587</pub-id></mixed-citation></ref><ref id="R6"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ontaneda</surname><given-names>D</given-names></name></person-group>. <article-title>Progressive multiple sclerosis.</article-title><source>Continuum (Minneap Minn)</source>. <year>2019</year>;<volume>25</volume>:<fpage>736</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">31162314</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/CON.0000000000000727</pub-id></mixed-citation></ref><ref id="R7"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lassmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Van Horssen</surname><given-names>J</given-names></name><name name-style="western"><surname>Mahad</surname><given-names>D</given-names></name></person-group>. <article-title>Progressive multiple sclerosis: pathology and pathogenesis.</article-title><source>Nat Rev Neurol</source>. <year>2012</year>;<volume>8</volume>:<fpage>647</fpage>&#8211;<lpage>56</lpage>.<pub-id pub-id-type="pmid">23007702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrneurol.2012.168</pub-id></mixed-citation></ref><ref id="R8"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>JWL</given-names></name><name name-style="western"><surname>Coles</surname><given-names>A</given-names></name><name name-style="western"><surname>Horakova</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis.</article-title><source>JAMA</source>. <year>2019</year>;<volume>321</volume>:<fpage>175</fpage>&#8211;<lpage>87</lpage>.<pub-id pub-id-type="pmid">30644981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2018.20588</pub-id><pub-id pub-id-type="pmcid">PMC6439772</pub-id></mixed-citation></ref><ref id="R9"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macaron</surname><given-names>G</given-names></name><name name-style="western"><surname>Ontaneda</surname><given-names>D</given-names></name></person-group>. <article-title>Diagnosis and management of progressive multiple sclerosis.</article-title><source>Biomedicines</source>. <year>2019</year>;<volume>7</volume>:<fpage>56</fpage>.<pub-id pub-id-type="pmid">31362384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines7030056</pub-id><pub-id pub-id-type="pmcid">PMC6784028</pub-id></mixed-citation></ref><ref id="R10"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hauser</surname><given-names>SL</given-names></name><name name-style="western"><surname>Cree</surname><given-names>BAC</given-names></name></person-group>. <article-title>Treatment of multiple sclerosis: a review.</article-title><source>Am J Med</source>. <year>2020</year>;<volume>133</volume>:<fpage>1380</fpage>&#8211;<lpage>90.e2</lpage>.<pub-id pub-id-type="pmid">32682869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjmed.2020.05.049</pub-id><pub-id pub-id-type="pmcid">PMC7704606</pub-id></mixed-citation></ref><ref id="R11"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ninkov</surname><given-names>A</given-names></name><name name-style="western"><surname>Frank</surname><given-names>JR</given-names></name><name name-style="western"><surname>Maggio</surname><given-names>LA</given-names></name></person-group>. <article-title>Bibliometrics: methods for studying academic publishing.</article-title><source>Perspect Med Educ</source>. <year>2022</year>;<volume>11</volume>:<fpage>173</fpage>&#8211;<lpage>6</lpage>.<pub-id pub-id-type="pmid">34914027</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40037-021-00695-4</pub-id><pub-id pub-id-type="pmcid">PMC9240160</pub-id></mixed-citation></ref><ref id="R12"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ismail</surname><given-names>II</given-names></name><name name-style="western"><surname>Saqr</surname><given-names>MA</given-names></name></person-group>. <article-title>Quantitative synthesis of eight decades of global multiple sclerosis research using bibliometrics.</article-title><source>Front Neurol</source>. <year>2022</year>;<volume>13</volume>:<fpage>845539</fpage>.<pub-id pub-id-type="pmid">35280299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fneur.2022.845539</pub-id><pub-id pub-id-type="pmcid">PMC8907526</pub-id></mixed-citation></ref><ref id="R13"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magliozzi</surname><given-names>R</given-names></name><name name-style="western"><surname>Howell</surname><given-names>O</given-names></name><name name-style="western"><surname>Vora</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology.</article-title><source>Brain</source>. <year>2007</year>;<volume>130</volume>:<fpage>1089</fpage>&#8211;<lpage>104</lpage>.<pub-id pub-id-type="pmid">17438020</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/brain/awm038</pub-id></mixed-citation></ref><ref id="R14"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kleinschmidt-DeMasters</surname><given-names>BK</given-names></name><name name-style="western"><surname>Tyler</surname><given-names>KL</given-names></name></person-group>. <article-title>Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.</article-title><source>N Engl J Med</source>. <year>2005</year>;<volume>353</volume>:<fpage>369</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="pmid">15947079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa051782</pub-id></mixed-citation></ref><ref id="R15"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name><name name-style="western"><surname>Polman</surname><given-names>C</given-names></name><name name-style="western"><surname>Pozzilli</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Placebo-controlled multicentre randomised trial of interferon &#946;-1b in treatment of secondary progressive multiple sclerosis.</article-title><source>Lancet</source>. <year>1998</year>;<volume>352</volume>:<fpage>1491</fpage>&#8211;<lpage>7</lpage>.<pub-id pub-id-type="pmid">9820296</pub-id></mixed-citation></ref><ref id="R16"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Montalban</surname><given-names>X</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>SL</given-names></name><name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Ocrelizumab versus placebo in primary progressive multiple sclerosis.</article-title><source>N Engl J Med</source>. <year>2017</year>;<volume>376</volume>:<fpage>209</fpage>&#8211;<lpage>20</lpage>.<pub-id pub-id-type="pmid">28002688</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1606468</pub-id></mixed-citation></ref><ref id="R17"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Serafini</surname><given-names>B</given-names></name><name name-style="western"><surname>Rosicarelli</surname><given-names>B</given-names></name><name name-style="western"><surname>Magliozzi</surname><given-names>R</given-names></name><name name-style="western"><surname>Stigliano</surname><given-names>E</given-names></name><name name-style="western"><surname>Aloisi</surname><given-names>F</given-names></name></person-group>. <article-title>Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.</article-title><source>Brain Pathol</source>. <year>2004</year>;<volume>14</volume>:<fpage>164</fpage>&#8211;<lpage>74</lpage>.<pub-id pub-id-type="pmid">15193029</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1750-3639.2004.tb00049.x</pub-id><pub-id pub-id-type="pmcid">PMC8095922</pub-id></mixed-citation></ref><ref id="R18"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartung</surname><given-names>HP</given-names></name><name name-style="western"><surname>Gonsette</surname><given-names>R</given-names></name><name name-style="western"><surname>K&#246;nig</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.</article-title><source>Lancet</source>. <year>2002</year>;<volume>360</volume>:<fpage>2018</fpage>&#8211;<lpage>25</lpage>.<pub-id pub-id-type="pmid">12504397</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(02)12023-X</pub-id></mixed-citation></ref><ref id="R19"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hauser</surname><given-names>SL</given-names></name><name name-style="western"><surname>Dawson</surname><given-names>DM</given-names></name><name name-style="western"><surname>Lehrich</surname><given-names>JR</given-names></name><etal/></person-group>. <article-title>Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.</article-title><source>N Engl J Med</source>. <year>1983</year>;<volume>308</volume>:<fpage>173</fpage>&#8211;<lpage>80</lpage>.<pub-id pub-id-type="pmid">6294517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJM198301273080401</pub-id></mixed-citation></ref><ref id="R20"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mahad</surname><given-names>DH</given-names></name><name name-style="western"><surname>Trapp</surname><given-names>BD</given-names></name><name name-style="western"><surname>Lassmann</surname><given-names>H</given-names></name></person-group>. <article-title>Pathological mechanisms in progressive multiple sclerosis.</article-title><source>Lancet Neurol</source>. <year>2015</year>;<volume>14</volume>:<fpage>183</fpage>&#8211;<lpage>93</lpage>.<pub-id pub-id-type="pmid">25772897</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(14)70256-X</pub-id></mixed-citation></ref><ref id="R21"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hawker</surname><given-names>K</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>P</given-names></name><name name-style="western"><surname>Freedman</surname><given-names>MS</given-names></name><etal/></person-group>. <article-title>Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.</article-title><source>Ann Neurol</source>. <year>2009</year>;<volume>66</volume>:<fpage>460</fpage>&#8211;<lpage>71</lpage>.<pub-id pub-id-type="pmid">19847908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ana.21867</pub-id></mixed-citation></ref><ref id="R22"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walton</surname><given-names>C</given-names></name><name name-style="western"><surname>King</surname><given-names>R</given-names></name><name name-style="western"><surname>Rechtman</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition.</article-title><source>Mult Scler</source>. <year>2020</year>;<volume>26</volume>:<fpage>1816</fpage>&#8211;<lpage>21</lpage>.<pub-id pub-id-type="pmid">33174475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1352458520970841</pub-id><pub-id pub-id-type="pmcid">PMC7720355</pub-id></mixed-citation></ref><ref id="R23"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alonso</surname><given-names>A</given-names></name><name name-style="western"><surname>Hern&#225;n</surname><given-names>MA</given-names></name></person-group>. <article-title>Temporal trends in the incidence of multiple sclerosis: a systematic review.</article-title><source>Neurology</source>. <year>2008</year>;<volume>71</volume>:<fpage>129</fpage>&#8211;<lpage>35</lpage>.<pub-id pub-id-type="pmid">18606967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1212/01.wnl.0000316802.35974.34</pub-id><pub-id pub-id-type="pmcid">PMC4109189</pub-id></mixed-citation></ref><ref id="R24"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Howard</surname><given-names>J</given-names></name><name name-style="western"><surname>Trevick</surname><given-names>S</given-names></name><name name-style="western"><surname>Younger</surname><given-names>DS</given-names></name></person-group>. <article-title>Epidemiology of multiple sclerosis.</article-title><source>Neurol Clin</source>. <year>2016</year>;<volume>34</volume>:<fpage>919</fpage>&#8211;<lpage>39</lpage>.<pub-id pub-id-type="pmid">27720001</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ncl.2016.06.016</pub-id></mixed-citation></ref><ref id="R25"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hua</surname><given-names>LH</given-names></name><name name-style="western"><surname>Hersh</surname><given-names>CM</given-names></name><name name-style="western"><surname>Tian</surname><given-names>F</given-names></name><name name-style="western"><surname>Mowry</surname><given-names>EM</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>KC</given-names></name></person-group>. <article-title>Clinical characteristics of a large multi-center cohort of people with multiple sclerosis over age 60.</article-title><source>Mult Scler Relat Disord</source>. <year>2021</year>;<volume>47</volume>:<fpage>102637</fpage>.<pub-id pub-id-type="pmid">33276238</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.msard.2020.102637</pub-id><pub-id pub-id-type="pmcid">PMC8293698</pub-id></mixed-citation></ref><ref id="R26"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scalfari</surname><given-names>A</given-names></name></person-group>. <article-title>MS progression is predominantly driven by age-related mechanisms &#8211; yes;</article-title><volume>25</volume>:<fpage>902</fpage>&#8211;<lpage>4</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1352458518820633</pub-id><pub-id pub-id-type="pmid">30747579</pub-id></mixed-citation></ref><ref id="R27"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>A</given-names></name><name name-style="western"><surname>Ciccarelli</surname><given-names>O</given-names></name></person-group>. <article-title>Towards treating progressive multiple sclerosis.</article-title><source>Nat Rev Neurol</source>. <year>2020</year>;<volume>16</volume>:<fpage>589</fpage>&#8211;<lpage>90</lpage>.<pub-id pub-id-type="pmid">33024328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41582-020-00421-4</pub-id></mixed-citation></ref><ref id="R28"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Absinta</surname><given-names>M</given-names></name><name name-style="western"><surname>Lassmann</surname><given-names>H</given-names></name><name name-style="western"><surname>Trapp</surname><given-names>BD</given-names></name></person-group>. <article-title>Mechanisms underlying progression in multiple sclerosis.</article-title><source>Curr Opin Neurol</source>. <year>2020</year>;<volume>33</volume>:<fpage>277</fpage>&#8211;<lpage>85</lpage>.<pub-id pub-id-type="pmid">32324705</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/WCO.0000000000000818</pub-id><pub-id pub-id-type="pmcid">PMC7337978</pub-id></mixed-citation></ref><ref id="R29"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kappos</surname><given-names>L</given-names></name><name name-style="western"><surname>Bar-Or</surname><given-names>A</given-names></name><name name-style="western"><surname>Cree</surname><given-names>BAC</given-names></name><etal/></person-group>. <article-title>Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.</article-title><source>Lancet</source>. <year>2018</year>;<volume>391</volume>:<fpage>1263</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">29576505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(18)30475-6</pub-id></mixed-citation></ref><ref id="R30"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aleixandre-Benavent</surname><given-names>R</given-names></name><name name-style="western"><surname>Alonso-Arroyo</surname><given-names>A</given-names></name><name name-style="western"><surname>Gonz&#225;lez De Dios</surname><given-names>J</given-names></name><name name-style="western"><surname>Vidal-Infer</surname><given-names>A</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Mu&#241;oz</surname><given-names>M</given-names></name><name name-style="western"><surname>Sempere</surname><given-names>AP</given-names></name></person-group>. <article-title>Bibliometric profile of the global scientific research on multiple sclerosis (2003-2012).</article-title><source>Mult Scler</source>. <year>2015</year>;<volume>21</volume>:<fpage>235</fpage>&#8211;<lpage>45</lpage>.<pub-id pub-id-type="pmid">25257610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1352458514540357</pub-id></mixed-citation></ref><ref id="R31"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caballero-Villarraso</surname><given-names>J</given-names></name><name name-style="western"><surname>Sawas</surname><given-names>J</given-names></name><name name-style="western"><surname>Escribano</surname><given-names>BM</given-names></name><name name-style="western"><surname>Mart&#237;n-Hersog</surname><given-names>FA</given-names></name><name name-style="western"><surname>Valverde-Mart&#237;nez</surname><given-names>A</given-names></name><name name-style="western"><surname>T&#250;nez</surname><given-names>I</given-names></name></person-group>. <article-title>Gene and cell therapy and nanomedicine for the treatment of multiple sclerosis: bibliometric analysis and systematic review of clinical outcomes.</article-title><source>Expert Rev Neurother</source>. <year>2021</year>;<volume>21</volume>:<fpage>431</fpage>&#8211;<lpage>41</lpage>.<pub-id pub-id-type="pmid">33554666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14737175.2021.1886926</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>